Wu Li-Sha, Wang Xiao-Wei, He Wen, Ma Xiao-Ting, Wang Hai-Yue, Han Mei, Li Bing-Hui
1 Department of Surgery, Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang, PR China.
2 Department of Biochemistry and Molecular Biology, College of Basic Medicine, Key Laboratory of Medical Biotechnology of Hebei Province, Hebei Medical University, Shijiazhuang, PR China.
J Int Med Res. 2019 Feb;47(2):962-972. doi: 10.1177/0300060518820785. Epub 2019 Jan 9.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic ligand that activates the extrinsic apoptosis pathway of cell death receptors. This study aimed to evaluate the relationship between TRAIL and platelet-induced tumor metastasis in colorectal cancer.
Platelet P-selectin (CD62P) was measured by immunohistochemistry in tumor and adjacent normal tissues from 90 patients with colorectal cancer undergoing resection. Tumor cell invasion was assessed by transwell assay in the presence of platelets with or without TRAIL. The expression of TRAIL receptors DR4 and DR5 on platelets was assessed by flow cytometry, real-time polymerase chain reaction, and western blotting.
P-selectin (CD62P) expression was significantly increased in tumor tissues compared with adjacent normal tissues. High CD62P expression was significantly correlated with tumor stage and vascular invasion. Tumor cell migration was increased by coculture with platelets, but this effect was inhibited by TRAIL. Transforming growth factor (TGF)-β1 secretion was significantly reduced in TRAIL-treated platelets. The TRAIL receptor DR5 but not DR4 was expressed in platelets according to flow cytometry.
TRAIL could inhibit metastasis and colon cancer cell invasion by promoting platelet apoptosis and reducing the release of TGF-β1.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)是一种促凋亡配体,可激活细胞死亡受体的外源性凋亡途径。本研究旨在评估TRAIL与血小板诱导的结直肠癌肿瘤转移之间的关系。
采用免疫组织化学法检测90例接受手术切除的结直肠癌患者肿瘤组织及癌旁正常组织中的血小板P-选择素(CD62P)。在有或无TRAIL的情况下,通过Transwell实验评估血小板存在时肿瘤细胞的侵袭情况。采用流式细胞术、实时聚合酶链反应和蛋白质印迹法评估血小板上TRAIL受体DR4和DR5的表达。
与癌旁正常组织相比,肿瘤组织中P-选择素(CD62P)表达显著增加。高CD62P表达与肿瘤分期和血管侵犯显著相关。与血小板共培养可增加肿瘤细胞迁移,但TRAIL可抑制这种作用。TRAIL处理的血小板中转化生长因子(TGF)-β1分泌显著减少。流式细胞术检测显示血小板中表达TRAIL受体DR5而非DR4。
TRAIL可通过促进血小板凋亡和减少TGF-β1释放来抑制结直肠癌转移和癌细胞侵袭。